Philadelphia – Thanksgiving is often a time for thinking about your belly. For those with an inflammatory bowel diseases like ulcerative colitis, feasting can be associated with stress, even when food isn’t a trigger for the painful symptoms. New research in mice suggests that certain foods – especially those high...
research News
Lausanne, Switzerland – As our battle against cancer rages on, the quest for more sophisticated and realistic models to study tumor development has never been more critical. Until now, research has relied on animal models and simplified cell culture methods, which are valuable but cannot fully capture the complex interplay...
BOULDER, Colo. – Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare muscle disorders, today announced the publication of the first cross-sectional, retrospective study to describe selective elevation of fast but not slow skeletal muscle fiber injury biomarkers in the...
An over-the-counter prostate cancer test kit could be coming to a pharmacy near you, thanks to the collaborative work of a University of Central Florida chemist and M.D. Anderson Cancer Center Orlando researchers. UCF’s Qun “Treen” Huo and M.D. Anderson-Orlando’s Dr. Cheryl Baker and Jimmie Colon teamed up about 18...
Use of a new diagnostic guideline for hypersensitivity pneumonitis (HP), published in 2020, has resulted in half of patients with HP also being diagnosed with idiopathic pulmonary fibrosis (IPF), according to authors of a recent study published in the American Journal of Respiratory and Critical Care Medicine. The investigators who conducted...
PALO ALTO, Calif. — Eiger BioPharmaceuticals, Inc, a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today announced that it and its partner AnGes, Inc. received marketing approval from the Ministry of Health, Labour and Welfare for Zokinvy (lonafarnib), a treatment for Hutchinson-Gilford progeria...
The investigational oral selective estrogen receptor degrader (SERD) elacestrant significantly decreased the risk of death or disease progression and increased progression-free survival compared with standard-of-care endocrine therapy for postmenopausal patients with estrogen receptor (ER)-positive/HER2-negative metastatic breast cancers that progressed on prior endocrine and targeted therapies, according to results from the...
BOSTON, Mass. — Elicio Therapeutics, Inc., a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that the first patient has been dosed at Northwell Health Cancer Institute and the Feinstein Institutes for Medical Research, New York, as part of the randomized Phase...
Blacksburg, VA – Every 65 seconds, someone in the United States develops Alzheimer’s disease, a devastating form of dementia that affects 6.2 million Americans. Though it was initially identified almost 120 years ago, Alzheimer’s disease is a progressive neurological disorder with no cure and few treatments. It starts out with minor...
LAS VEGAS — Muscular dystrophies encompass a range of muscle disorders resulting from genetic mutations. Over time, these conditions lead to muscle weakness, which hinders everyday activities. Muscular dystrophy takes various forms, each targeting specific muscle groups and manifesting at different ages with varying degrees of severity. It can either...